Neuphoria Therapeutics NEUP
NASDAQ NEUP
$2.71 +0.02 (+0.74%)
At close: Nov 11, 2026 · 4:00 PM EST

Neuphoria Therapeutics (NEUP) Return on Sales [ROS] (2024 - 2025)

Updated

Neuphoria Therapeutics' Return on Sales [ROS] came in at -1401.09% for FY2026 (year ended Jun 30, 2026), down 1393.87 percentage points from -7.21% in FY2025.

Analysis

Neuphoria Therapeutics (NEUP) Return on Sales [ROS] (2024 - 2025) Analysis & Trends

Going back to FY2020, Neuphoria Therapeutics' Return on Sales [ROS] data covers 5 fiscal years.

  • Return on Sales [ROS] carries a four-year change of +6908.54 percentage points (FY2022 to FY2026).
  • The FY2026 figure represents the lowest annual Return on Sales [ROS] since FY2023.
  • Per Business Quant, earlier fiscal years put Return on Sales [ROS] at -7.21% in FY2025, -145255.68% in FY2023 (-136946.05 pp) and -8309.63% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Neuphoria Therapeutics 335.34 Mn 260.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -7.20%
Mar 31, 2025 79.85%
Dec 31, 2024 -558.84%
API Access

Neuphoria Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NEUP&period=max&api_key=YOUR_API_KEY